Innoviva (NASDAQ:INVA) is a biopharmaceutical royalty and specialty finance company headquartered in San Francisco, California. Established in 2014 as a spin-off from Theravance, Inc., Innoviva focuses on acquiring, managing and monetizing royalty interests in respiratory and antibacterial products originally discovered by Theravance. The company’s core strategy centers on collecting royalty revenues and deploying capital to generate long-term shareholder value.
Innoviva holds significant royalty interests in a portfolio of respiratory medications marketed globally by GSK, including products for chronic obstructive pulmonary disease (COPD) and asthma. Its royalty rights encompass key brands such as Breo® Ellipta®, Anoro® Ellipta® and Trelegy® Ellipta®, among others. In addition, Innoviva has interests in antibacterial therapies developed through its collaboration with Theravance, which broadens its exposure to anti-infective markets.
Beyond royalties, Innoviva maintains a disciplined capital deployment framework, selectively investing in pharmaceutical and biotechnology ventures. These strategic equity investments complement its royalty business by providing exposure to early-stage innovation in areas such as respiratory, infectious disease and specialty therapeutics. The company reinvests a portion of its royalty proceeds to back next-generation assets and partnerships that align with its risk-adjusted return objectives.
Innoviva’s operations span North America, Europe, Asia and Latin America, reflecting the global reach of its pharmaceutical partners. The company is governed by an experienced board of directors and a management team with deep expertise in drug development, licensing and financial structuring. Innoviva’s streamlined corporate structure and focused mission enable it to support ongoing growth while delivering consistent royalty-based cash flows for its shareholders.
